BRNS vs. PBYI, IPHA, BMEA, CDTX, STRO, FATE, TCRX, INMB, RENB, and KYTX
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Puma Biotechnology (PBYI), Innate Pharma (IPHA), Biomea Fusion (BMEA), Cidara Therapeutics (CDTX), Sutro Biopharma (STRO), Fate Therapeutics (FATE), TScan Therapeutics (TCRX), INmune Bio (INMB), Renovaro (RENB), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.
Barinthus Biotherapeutics vs.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
Puma Biotechnology has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Puma Biotechnology has a net margin of 9.56% compared to Barinthus Biotherapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Barinthus Biotherapeutics' return on equity.
Barinthus Biotherapeutics currently has a consensus target price of $5.17, indicating a potential upside of 396.79%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 135.69%. Given Barinthus Biotherapeutics' higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than Puma Biotechnology.
In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 8 mentions for Barinthus Biotherapeutics and 7 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.47 beat Barinthus Biotherapeutics' score of -0.01 indicating that Puma Biotechnology is being referred to more favorably in the news media.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Puma Biotechnology received 536 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 67.11% of users gave Puma Biotechnology an outperform vote.
Summary
Puma Biotechnology beats Barinthus Biotherapeutics on 12 of the 17 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BRNS) was last updated on 1/18/2025 by MarketBeat.com Staff
Free BRNS Stock Alerts